Cushing Disease in 2026: Updated Diagnostic Algorithms and Targeted Therapies

Introduction: A Resurgence of Attention, Not Proven Incidence

Cushing disease is the pituitary form of endogenous Cushing syndrome. An ACTH-secreting corticotroph tumor stimulates the adrenal glands to produce excess cortisol. Cushing syndrome is the broader category and also includes adrenal cortisol excess and ectopic ACTH secretion. That distinction matters because the localization tests, surgical strategy, approved indications, and monitoring plans differ substantially across these conditions. [1],[3]

There is no solid basis for claiming that pituitary Cushing disease itself is suddenly becoming more common. The real resurgence is in diagnostic attention and therapeutic choice. Clinicians now have better guidance for serial cortisol testing, modern pituitary MRI, standardized IPSS, and several U.S.-approved drugs that act at different levels of the hypothalamic-pituitary-adrenal axis. [3],[4],[5],[8]

Why Cushing Disease Still Evades Early Diagnosis

Most individual findings are nonspecific. Weight gain, hypertension, diabetes, depression, fatigue, menstrual disturbance, and osteoporosis are common in general practice. Suspicion should rise when several features are progressive, occur at an unusual age, or include more discriminatory findings such as proximal muscle weakness, wide violaceous striae, facial plethora, easy bruising, unexplained hypokalemia, or rapid multisystem deterioration. [1],[2]

The diagnostic challenge is compounded by two opposing problems. Mild and cyclic disease can produce normal results between active phases. At the same time, alcohol use disorder, major depression, severe obesity, sleep disruption, poorly controlled diabetes, acute illness, pregnancy, estrogen exposure, altered dexamethasone metabolism, and collection errors can all create misleading results. The diagnostic task is therefore to establish persistent or recurrent autonomous cortisol excess in the correct clinical context, not merely to obtain one abnormal number. [2],[3]

A Six-Stage Diagnostic Algorithm

Stage 1: Exclude Exogenous Glucocorticoid Exposure

Before biochemical testing begins, review all sources of glucocorticoid exposure. This includes oral, injected, inhaled, intranasal, topical, ophthalmic, and compounded products, as well as intermittent procedures and medications obtained outside the usual health record. Exogenous glucocorticoid exposure can produce Cushing syndrome and can make endogenous testing uninterpretable. [2]

Stage 2: Confirm Endogenous Hypercortisolism With an Appropriate First-Line Test

Recommended initial options include at least two late-night salivary cortisol (LNSC) measurements, at least two 24-hour urinary free cortisol (UFC) collections, a 1-mg overnight dexamethasone suppression test, or the longer low-dose dexamethasone suppression test. The choice among these should reflect sleep schedule, kidney function, estrogen use, medication interactions, collection reliability, and the suspected degree or cyclicity of cortisol excess. Random serum cortisol and random ACTH are not screening tests for Cushing syndrome. [2],[3]

Summary of First-Line Diagnostic Tests

Test	What it samples	Useful setting	Major pitfalls
Late-night salivary cortisol	Loss of the normal nighttime nadir [2],[3]	Mild disease, repeated home sampling, suspected cyclic disease, and longitudinal monitoring [2],[3],[6]	Shift work, irregular sleep, smoking, oral contamination, assay differences, and incorrect collection timing [2],[3],[6]
24-hour urinary free cortisol	Integrated unbound cortisol excretion [2],[3]	More overt hypercortisolism and serial response assessment [2],[3]	Incomplete collection, high fluid intake, reduced kidney function, and normal values during mild or inactive cyclic phases [2],[3]
1-mg overnight dexamethasone suppression	Failure of feedback suppression [2]	Convenient outpatient screening when medication and estrogen confounding can be controlled [2]	CYP3A4 inducers or inhibitors, estrogen-related cortisol-binding globulin elevation, nonadherence, and variable dexamethasone exposure [2]
Midnight serum cortisol or specialized dynamic testing	Circadian loss or differential response [2],[3],[4]	Selected equivocal cases in specialist centers [2],[3],[4]	Hospitalization and stress effects; protocol and assay dependence; no single dynamic test is definitive in all patients [2],[3],[4]

An abnormal result should usually be confirmed with another recommended test. Concordant normal results generally argue against Cushing syndrome unless pretest probability is high or cyclic disease is suspected. Concordant abnormal results support progression to etiologic evaluation after confounders are addressed. Discordant results require repetition, review of assay and collection quality, and often testing during a clinically active phase. [2],[3],[4]

Stage 3: Determine Whether the Disease Is ACTH-Dependent

Once endogenous hypercortisolism is established, obtain plasma ACTH using the local assay and careful sample handling. A suppressed ACTH pattern points toward an adrenal source. A clearly measurable or elevated ACTH supports ACTH-dependent disease and triggers differentiation between pituitary Cushing disease and ectopic ACTH secretion. Borderline values should be repeated rather than forced into a rigid universal cutoff. [1],[3],[4]

Stage 4: Obtain Optimized Pituitary MRI

High-resolution pituitary MRI with a dedicated protocol, thin sections, and dynamic contrast imaging when appropriate is the first-line localization study for suspected Cushing disease. A negative MRI does not exclude a corticotroph tumor, and a small pituitary lesion does not prove that the pituitary is the ACTH source. Incidental pituitary lesions are common enough that imaging must always be interpreted alongside the biochemical phenotype. [3],[4]

Stage 5: Use IPSS Selectively and Correctly

IPSS is the reference invasive localization procedure when ACTH-dependent Cushing syndrome is biochemically established but pituitary imaging is normal, equivocal, shows a lesion smaller than 6 mm, or conflicts with other findings. For lesions 6 to 9 mm, the decision is individualized. A lesion at least 10 mm with a fully concordant pituitary biochemical picture often does not require IPSS, although unusual or discordant cases still warrant expert review. [3],[5]

Modern IPSS practice uses bilateral catheterization, parallel peripheral sampling, ACTH stimulation with corticotropin-releasing hormone or desmopressin, rapid specimen handling, and often prolactin as an internal control of pituitary venous effluent. A central-to-peripheral ACTH ratio of at least 2 before stimulation or at least 3 after stimulation supports a pituitary source. These ratios are meaningful only when the patient is actively hypercortisolemic and the procedure is technically adequate. [5]

Two critical points deserve emphasis. IPSS should not be used to establish that Cushing syndrome exists. Interpetrosal gradients are also not reliable enough to dictate the side of surgical exploration by themselves because venous drainage can be asymmetric. [3],[5]

Pituitary MRI Findings and Practical Next Steps

Pituitary MRI finding	Practical next step when ACTH-dependent hypercortisolism is confirmed
No lesion or equivocal finding	Proceed to expert IPSS unless an ectopic source has already been established. [3],[5]
Lesion smaller than 6 mm	IPSS is generally recommended before pituitary surgery. [3],[5]
Lesion 6 to 9 mm	Individualize according to biochemical concordance, imaging quality, ectopic risk, and local expert practice. [3]
Lesion at least 10 mm	IPSS is often unnecessary when the clinical and biochemical evidence is convincingly pituitary, but discordance should trigger further review. [3]

Stage 6: Stop and Reconcile Discordant Data

The highest-risk error in the entire diagnostic pathway is operating on an incidental pituitary lesion after incomplete biochemical confirmation. When the phenotype, cortisol tests, ACTH, MRI, and IPSS do not tell the same story, return to the earliest uncertain step. Repeat testing during an active phase, verify dexamethasone exposure or urine completeness when relevant, review the assay, and reconsider ectopic ACTH secretion. [2],[3],[4],[5]

What Is Actually New in the 2026 Diagnostic Toolkit?

Several developments have refined the diagnostic approach without fundamentally altering its logic.

Serial home sampling is becoming more important. LNSC can capture day-to-day variability and is frequently used by experts for mild disease, postoperative surveillance, and monitoring during medical or radiation therapy. A 2026 Pituitary Society Delphi panel also identified restoration of circadian cortisol rhythm as a treatment goal, not merely normalization of a single integrated measure. [6],[9]

Assay context matters. Cortisol cutoffs are not fully portable across immunoassays, liquid chromatography-tandem mass spectrometry methods, regions, or clinical states. The report, local reference range, collection protocol, and medication list must be interpreted together. [3],[4],[6]

IPSS is becoming more standardized. The 2026 technical guideline clarifies indications, bilateral technique, stimulation, sample timing, ACTH handling, prolactin control, and false-negative prevention. Standardization reduces avoidable technical ambiguity, but it does not eliminate the need for an experienced multidisciplinary team. [5]

Investigational tools remain investigational. Investigational biomarkers and advanced imaging approaches remain research tools. None should replace validated biochemical confirmation, optimized MRI, or properly performed IPSS in routine practice. [3],[4],[6]

Treatment Begins With Source Control

Expert Transsphenoidal Surgery Remains First-Line

For a resectable ACTH-secreting pituitary tumor, selective transsphenoidal adenomectomy by an experienced pituitary surgeon remains the preferred first treatment. The goal is durable remission while preserving normal pituitary function. Outcome depends on tumor visibility, size, invasion, prior surgery, and surgeon and center experience. [3],[7]

Severe hypercortisolism may need medical control before surgery when immediate operation is unsafe or delayed. Preoperative therapy is not automatic for every patient. It is used when the risk of uncontrolled cortisol excess outweighs the delay or complexity introduced by treatment. [7],[8]

Postoperative Care Is Part of the Treatment, Not an Afterthought

Early postoperative assessment includes serum cortisol, glucocorticoid replacement when indicated, sodium and water balance, other pituitary axes, venous thromboembolism risk, infection risk, blood pressure, glucose, and wound or neurologic complications. Patients who enter remission may need glucocorticoid replacement while the hypothalamic-pituitary-adrenal axis recovers. [3],[7]

Recurrence can occur years later. Lifelong surveillance should combine clinical review with appropriate biochemical testing. LNSC is often useful because loss of the late-night nadir may precede a clearly elevated UFC, although assay-specific performance and repeated confirmation remain important. [3],[6],[9]

Persistent or Recurrent Disease: Choosing the Right Target

After noncurative surgery or recurrence, the major options are repeat pituitary surgery, pituitary radiation, medical therapy, and bilateral adrenalectomy. Choice depends on whether a resectable residual tumor is visible, the urgency of cortisol control, prior treatment, tumor behavior, fertility goals, comorbidities, and patient preference. [3],[7],[8]

Medical therapy can target the pituitary tumor, adrenal cortisol synthesis, or the glucocorticoid receptor. These categories are not interchangeable. Pituitary-directed treatment may reduce ACTH and tumor activity. Adrenal-directed treatment lowers cortisol but does not treat the pituitary tumor. Receptor blockade reduces cortisol action while circulating cortisol may remain elevated or increase. [3],[8]

Current U.S. Drug Options by Mechanism and Target

Agent and target	Current U.S. role	Label-based starting approach	Key clinical cautions
Pasireotide, pituitary somatostatin receptor ligand	Approved for Cushing disease when pituitary surgery is not an option or has not been curative. [10],[12]	Subcutaneous formulation: 0.6 or 0.9 mg twice daily, with a labeled range of 0.3 to 0.9 mg twice daily. Long-acting formulation: 10 mg intramuscularly every 28 days; after 4 months it may be increased, up to 40 mg every 28 days, according to response and tolerance. [10],[12]	Hyperglycemia can be substantial. Check fasting glucose, hemoglobin A1c, liver tests, ECG, potassium, magnesium, and gallbladder status as directed by the formulation’s label. Monitor for hypocortisolism, bradycardia or QT issues, hepatotoxicity, and gallbladder disease. [10],[11],[12],[13]
Osilodrostat, adrenal 11 beta-hydroxylase inhibitor	Approved for endogenous hypercortisolemia in adults with Cushing syndrome when surgery is not an option or has not been curative. [14]	Start 2 mg orally twice daily. Increase by 1 to 2 mg twice daily no more often than every 2 weeks; maximum 30 mg twice daily. [14]	Correct potassium and magnesium and obtain a baseline ECG. Monitor cortisol closely for hypocortisolism and recognize precursor-related effects such as hypertension, hypokalemia, edema, acne, or hirsutism. [14],[15],[16]
Levoketoconazole, adrenal steroidogenesis inhibitor	Approved for endogenous hypercortisolemia in adults with Cushing syndrome when surgery is not an option or has not been curative. It is not approved as an antifungal. [17]	Start 150 mg orally twice daily. Increase the total daily dose by 150 mg no more often than every 2 to 3 weeks; maximum 600 mg twice daily. [17]	Boxed warnings address hepatotoxicity and QT prolongation. Baseline and serial liver testing, ECG and electrolyte assessment, interaction review, and rapid action for liver injury or marked QT prolongation are essential. [17],[18],[19]
Mifepristone, glucocorticoid receptor antagonist	Approved only to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not surgical candidates. [20]	Start 300 mg orally once daily with a meal. Increase in 300-mg increments no more often than every 2 to 4 weeks; maximum 1200 mg daily or 20 mg/kg daily, whichever is lower. [20]	Pregnancy is contraindicated and the label has a boxed warning for termination of pregnancy. Monitor clinical response rather than aiming for cortisol normalization. Watch for hypokalemia, signs of excessive glucocorticoid blockade, endometrial changes, QT effects, and major drug interactions. [20],[21]
Cabergoline, pituitary dopamine agonist	Off-label in the United States. It may be considered in selected mild persistent or recurrent Cushing disease under specialist care. [3],[8],[22],[23]	No standardized Cushing regimen is FDA-approved; published observational regimens require specialist titration. [22],[23]	An individual participant meta-analysis of small observational studies found biochemical remission in about one-third of treated patients. Durability is variable, and adverse effects and monitoring should be individualized. [23]

In the United States, metyrapone, ketoconazole, and intravenous etomidate are used off-label to control hypercortisolism. They remain important in specialist practice, and etomidate can be used for severe disease when oral treatment is not possible. Selection, dosing, interactions, hepatic risk, androgen or mineralocorticoid precursor effects, and inpatient monitoring requirements differ across these agents. [7],[8]

Assessing the Strength of the Treatment Trial Evidence

Understanding the quality and limitations of the evidence behind each medication is essential for informed clinical decision-making.

Pasireotide demonstrated urinary cortisol reduction and clinical improvement in both subcutaneous and monthly formulation phase 3 programs. However, hyperglycemia is a defining treatment burden that requires proactive management. [11],[13]

Osilodrostat has both randomized-withdrawal and placebo-controlled phase 3 evidence. In LINC 4, 77% of patients assigned osilodrostat versus 8% assigned placebo achieved mean UFC at or below the upper limit of normal at week 12. Hypocortisolism and adrenal precursor effects require active monitoring and dose adjustment. [15],[16]

Levoketoconazole showed cortisol-lowering activity in the open-label SONICS study, and the LOGICS withdrawal trial demonstrated that loss of control was substantially more common after switch to placebo than with continued therapy. Its efficacy must be weighed against boxed liver and QT risks. [17],[18],[19]

Mifepristone improved glucose and other clinical measures in a 24-week open-label study, but receptor blockade makes cortisol concentrations unsuitable as a direct treatment target. The clinician must recognize adrenal insufficiency-like symptoms despite high circulating cortisol and follow current labeling and specialist protocols for treatment interruption and reversal when excessive glucocorticoid receptor blockade is suspected. [20],[21]

Cross-trial response percentages should not be used as a ranking table. Trials differ in disease severity, prior surgery, endpoints, assay methods, titration rules, rescue criteria, and responder enrichment. No head-to-head randomized trial establishes one drug as best for all patients. [3],[8]

A Practical Mechanism-Based Selection Framework

When Cortisol Control Is Urgent

Severe infection, profound hypokalemia, psychosis, rapidly worsening diabetes, heart failure, thromboembolism, or catabolic deterioration can make hypercortisolism an endocrine emergency. Rapid adrenal steroidogenesis inhibition, combination therapy, or a block-and-replace strategy may be appropriate in an expert center. Intravenous etomidate is an option when oral treatment cannot be used. Frequent cortisol, electrolyte, glucose, blood pressure, fluid, and clinical adrenal-insufficiency monitoring is required. [6],[7],[8]

When Tumor-Directed Therapy Is the Priority

Repeat surgery is most attractive when a discrete, surgically accessible residual or recurrent pituitary tumor is visible. Pituitary radiation can provide delayed control and may be useful for unresectable or repeatedly recurrent disease, but medical bridging is often required and long-term hypopituitarism surveillance is mandatory. Pasireotide or off-label cabergoline may provide pituitary-directed medical therapy, whereas adrenal inhibitors do not directly control corticotroph tumor growth. [3],[7],[8]

When Comorbidity Should Drive the Drug Choice

Marked baseline hyperglycemia may make pasireotide difficult unless glucose treatment can be intensified. Mifepristone has a specifically labeled role when hyperglycemia is the dominant manifestation and the patient meets all indication and safety criteria. Significant liver disease, high-risk QT prolongation, or interacting drugs can exclude levoketoconazole. Hypokalemia, hypertension, androgenic symptoms, or QT risk may complicate osilodrostat. Reproductive plans and pregnancy potential are central to every choice, particularly because mifepristone is contraindicated in pregnancy. [10],[12],[14],[17],[20]

When Biochemical Normalization Is Not Enough

Monitoring should include the marker that fits the drug mechanism and the patient’s disease pattern, plus blood pressure, glucose, potassium, weight, muscle strength, psychiatric symptoms, infection, thrombosis, bone health, reproductive function, and quality of life. With mifepristone, clinical and metabolic response replaces cortisol normalization as the central efficacy measure. With synthesis inhibitors, biochemical control must be balanced against symptoms of hypocortisolism. With any long-term drug, planned reassessment should ask whether definitive surgery, radiation, or bilateral adrenalectomy has become a better option. [6],[8],[20],[24]

Radiation and Bilateral Adrenalectomy Still Have Essential Roles

Pituitary radiation can provide durable control when surgery is unsuccessful or not feasible, but the effect is delayed. Medical therapy is commonly used while awaiting response, and lifelong surveillance for hypopituitarism and tumor behavior is necessary. [3],[7]

Bilateral adrenalectomy provides rapid, definitive control of adrenal cortisol production when other strategies cannot control severe disease. It also creates permanent adrenal insufficiency requiring lifelong glucocorticoid and mineralocorticoid replacement, emergency steroid education, and adrenal-crisis prevention. ACTH and pituitary imaging must continue because corticotroph tumor progression can occur after adrenalectomy. [3],[7]

Emerging Targeted Therapies: Promising but Not Yet Routine

Relacorilant is a selective glucocorticoid receptor modulator. The phase 3 GRACE randomized-withdrawal study reported better maintenance of hypertension response among selected responders who continued relacorilant than among those switched to placebo. However, the Cushing indication was not FDA-approved as of August 20, 2026, so the drug remains investigational for this use. [25],[26]

Atumelnant is an oral melanocortin 2 receptor antagonist designed to block ACTH signaling at the adrenal cortex. A phase 2/3 program is registered in ACTH-dependent Cushing syndrome, including randomized placebo-controlled and block-and-replace components. It remains investigational, and the registry does not provide completed phase 2/3 efficacy results. [27]

Other tumor-genotype, receptor, and signaling strategies remain research tools. At present, the clinically actionable targets are still the pituitary source, adrenal cortisol synthesis, and glucocorticoid receptor, selected within a multidisciplinary care plan. [3],[8]

Managing the Persistent Cortisol-Related Comorbidity Burden

Controlling cortisol does not instantly reverse cardiovascular, thrombotic, metabolic, skeletal, muscular, psychiatric, infectious, or reproductive risk. Management should include active treatment of hypertension and diabetes, individualized venous thromboembolism assessment, infection vigilance, bone-density and fracture evaluation, psychiatric care, rehabilitation for myopathy, and reproductive counseling. Some morbidity persists after biochemical remission, which is one reason long-term follow-up must extend beyond tumor and cortisol testing. [1],[3],[7]

A Clinician Checklist for Managing Cushing Disease

1. Confirm that glucocorticoid exposure has been excluded and that endogenous hypercortisolism is established with valid, repeated testing. [2]
2. Classify ACTH dependence before ordering localization procedures. [1],[3]
3. Use dedicated pituitary MRI, but do not let a small lesion override discordant biochemistry. [3],[4]
4. Use IPSS only in confirmed ACTH-dependent disease and only in an experienced center with standardized sampling and interpretation. [5]
5. Refer surgical candidates to an experienced pituitary surgeon. [3],[7]
6. When medication is needed, choose by target, urgency, label, comorbidity, interaction profile, reproductive risk, and monitoring capacity. [8],[10],[12],[14],[17],[20]
7. Educate every patient receiving cortisol-lowering or receptor-blocking therapy about symptoms that require urgent assessment for adrenal insufficiency or excessive glucocorticoid blockade. [8],[10],[12],[14],[17],[20]
8. Reassess for recurrence and persistent comorbidity for life. [3],[6],[9]

Acknowledging the Current Limitations of the Evidence Base

Cushing disease is rare, so many treatment studies are small, open-label, single-arm, or randomized-withdrawal trials enriched for initial responders. Urinary cortisol normalization is an important biochemical outcome but does not by itself establish durable remission, restored circadian physiology, tumor control, reversal of comorbidities, or improved survival. Assay differences and variable definitions of response limit comparison across studies. Long-term evidence for sequencing and combination therapy remains less certain than evidence for short-term biochemical control. [3],[6],[8],[15],[16],[18],[19],[21],[23],[24],[25]

Conclusion: Defining the New Era of Cushing Disease Management

The contemporary management of Cushing disease is more precise because the sequence is clearer. Confirm endogenous hypercortisolism, determine ACTH dependence, localize carefully, and do not operate on an incidental MRI finding. Use expert pituitary surgery when a curative operation is feasible. When it is not, select medical treatment according to the biologic target and the patient’s dominant risks, and retain radiation or bilateral adrenalectomy when they provide the best route to durable control. The new era is defined less by one breakthrough than by disciplined integration of biomarkers, imaging, invasive localization, surgery, and mechanism-based therapy. [3],[4],[5],[6],[7],[8]

References

1. Reincke M, Fleseriu M. Cushing Syndrome: A Review. JAMA. 2023;330(2):170-181. DOI. PMID: 37432427.
2. Nieman LK, Biller BMK, Findling JW, et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. DOI. PMID: 18334580.
3. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847-875. DOI. PMID: 34687601.
4. Lee J, Fukuoka H, Park SS, et al. Consensus on the Diagnosis of Cushing’s Disease: A Collaborative Statement from the Korean Endocrine Society and Japan Endocrine Society. Endocrinol Metab (Seoul). 2026;41(1):1-13. DOI. PMID: 41479209.
5. Siddiq F, Brooks H, Demirtas E, et al. Consensus Guidelines on Inferior Petrosal Sinus Sampling: A Guideline From the Society of Vascular and Interventional Neurology Guidelines and Practice Standards Committee. Stroke Vasc Interv Neurol. 2026;6(3):e002309. DOI. PMID: 42088331.
6. Fleseriu M, Biller BMK, Bancos I, et al. Consensus on Biomarker Utility for ACTH-Dependent Cushing’s Syndrome: A Pituitary Society Modified Delphi Panel. J Clin Endocrinol Metab. 2026 Jul 16:dgag279. Online ahead of print. DOI. PMID: 42460773.
7. Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831. DOI. PMID: 26222757.
8. Araujo-Castro M, Lamas C, Nowak E, et al. Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome. Endocr Rev. 2026;47(3):301-328. DOI. PMID: 41489578.
9. Amlashi FG, Swearingen B, Faje AT, et al. Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing’s Disease. J Clin Endocrinol Metab. 2015;100(10):3770-3777. DOI. PMID: 26196950.
10. DailyMed. SIGNIFOR (pasireotide) injection, U.S. prescribing information. Revised July 2024. Accessed August 20, 2026. Official source.
11. Colao A, Petersenn S, Newell-Price J, et al. A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease. N Engl J Med. 2012;366(10):914-924. DOI. PMID: 22397653.
12. DailyMed. SIGNIFOR LAR (pasireotide) kit, U.S. prescribing information. Accessed August 20, 2026. Official source.
13. Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17-26. DOI. PMID: 29032078.
14. DailyMed. ISTURISA (osilodrostat) tablets, U.S. prescribing information. Updated November 18, 2025. Accessed August 20, 2026. Official source.
15. Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020;8(9):748-761. DOI. PMID: 32730798.
16. Gadelha M, Bex M, Feelders RA, et al. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab. 2022;107(7):e2882-e2895. DOI. PMID: 35325149.
17. DailyMed. RECORLEV (levoketoconazole) tablets, U.S. prescribing information. Updated March 10, 2026. Accessed August 20, 2026. Official source.
18. Fleseriu M, Pivonello R, Elenkova A, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019;7(11):855-865. DOI. PMID: 31542384.
19. Pivonello R, Zacharieva S, Elenkova A, et al. Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary. 2022;25(6):911-926. DOI. PMID: 36085339.
20. DailyMed. KORLYM (mifepristone) tablets, U.S. prescribing information. Accessed August 20, 2026. Official source.
21. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049. DOI. PMID: 22466348.
22. DailyMed. CABERGOLINE tablets, U.S. prescribing information. Accessed August 20, 2026. Official source.
23. Palui R, Sahoo J, Kamalanathan S, et al. Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis. J Endocrinol Invest. 2018;41(12):1445-1455. DOI. PMID: 30097903.
24. Ghalawinji A, Drezet L, Chaffanjon P, et al. Discontinuation of Drug Treatment in Cushing’s Disease Not Cured by Pituitary Surgery. J Clin Endocrinol Metab. 2024;109(4):1000-1011. DOI. PMID: 37962981.
25. Pivonello R, Arnaldi G, Auchus RJ, et al. Efficacy and safety of relacorilant for the treatment of patients with Cushing’s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. Lancet Diabetes Endocrinol. 2026;14(4):291-304. DOI. PMID: 41730814.
26. U.S. Food and Drug Administration. Orphan Drug Designations and Approvals: relacorilant for treatment of endogenous Cushing syndrome. Accessed August 20, 2026. Official source.
27. Australian New Zealand Clinical Trials Registry. ACTRN12626000211369: A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (EQUILIBRIUM ADCS), Part A. Registered February 20, 2026; last updated June 12, 2026. Accessed August 20, 2026. Official source.